Jefferies initiates buy on Krystal Biotech with a $245 price target, citing Vyjuvek's strong growth potential and proprietary ...
Jefferies analyst Roger Song initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $245 price target Krystal is a commercial ...
Russia plans to increase procurements of drugs against rare diseases despite the current tough business environment and ...
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Zacks Small Cap Research on MSN2d
LGND: First Steps into Cell & Gene TherapyLGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its ...
Eli Lilly and Co. to discover, develop and commercialize molecular glue therapeutics for oncology. “It’s a really important deal, especially given the discovery of Trueglues is something Magnet is ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Vyjuvek for the ...
Krystal Biotech (KRYS) has received a positive recommendation from EU regulators for its drug Vyjuvek for the treatment of ...
CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...
Krystal said it is on track to launch Vyjuvek in Germany in the middle of the year and in France later in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback